News LEO bulks up with deal for Boehringer skin drug LEO Pharma has licensed a medicine for a rare form of psoriasis from Boehringer Ingelheim, plugging a gap in its near-term product portfolio.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
